Overview

An Open-Label Pharmacodynamic Study of Bevacivumab and Pazopanib in Renal Cell Carcinoma

Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
This study will determine whether blood tests, tumour imaging and tumour tissue analysis can reveal effects of drugs that block blood vessel growth (angiogenesis) in patients with renal cancer.
Phase:
Phase 1
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Bevacizumab